Mesoblast (MESO) Interest Expenses (2014 - 2023)
Mesoblast (MESO) posted Interest Expenses of $4.5 million for Q2 2023, down 71.59% sequentially from $15.7 million in Q1 2023, and down 79.39% YoY from $21.6 million in Q2 2022.
Mesoblast (MESO) Interest Expenses (2014 - 2023) Analysis & Trends
Mesoblast has reported Interest Expenses for 10 years, with the latest figure at $4.5 million in Q2 2023.
- Quarterly Interest Expenses fell 79.39% year-over-year to $4.5 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was $4.5 million (down 85.45% YoY) and the FY2025 annual result came in at $23.0 million, changed 0.18% from the prior year.
- Interest Expenses declined to $4.5 million in Q2 2023 per MESO's latest filing, from $15.7 million in the prior quarter.
- Over five years, Interest Expenses peaked at $21.6 million in Q2 2022 and troughed at -$5.4 million in Q4 2021.
- A 5-year average of $6.3 million and a median of $4.0 million in 2020 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2019 and 2021: Interest Expenses jumped 843.26% in 2019, then tumbled 234.7% in 2021.
- Over 5 years, Interest Expenses stood at $3.6 million in 2019, then grew by 10.88% to $4.0 million in 2020, then sank by 234.7% to -$5.4 million in 2021, then surged by 298.61% to $10.7 million in 2022, then tumbled by 58.33% to $4.5 million in 2023.
- According to Business Quant data, Interest Expenses over the past three periods registered $4.5 million, $15.7 million, and $10.7 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 4.45 Mn |
| Jun 30, 2023 | 4.45 Mn |
| Mar 31, 2023 | 15.67 Mn |
| Mar 31, 2023 | 15.67 Mn |
| Dec 31, 2022 | 10.69 Mn |
| Dec 31, 2022 | 10.69 Mn |
| Sep 30, 2022 | 4.55 Mn |
| Sep 30, 2022 | 4.55 Mn |
| Jun 30, 2022 | 21.61 Mn |
| Jun 30, 2022 | 21.61 Mn |
| Mar 31, 2022 | 12.95 Mn |
| Mar 31, 2022 | 12.95 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | 4.14 Mn |
| Sep 30, 2021 | 4.14 Mn |
| Jun 30, 2021 | 4.07 Mn |
| Jun 30, 2021 | 4.07 Mn |
| Mar 31, 2021 | 3.95 Mn |
| Mar 31, 2021 | 3.95 Mn |